Facts and Figures
Of the 374 products currently in development for neglected diseases, 201 (54%) are vaccines targeted to 16 specific neglected diseases or diseases that disproportionately affect the poorest countries.1
Many of the most prevalent diseases, such as malaria, tuberculosis, dengue, leishmaniasis, shistosomiasis, cholera, and pneumoccocal infections, have multiple vaccines in various stages of development.2
Forty percent (40%) of the R&D under way for neglected diseases is conducted through product development partnerships (PDPs).
13 large pharmaceutical companies are participating in the development of 65 (17%) drugs or vaccines for neglected diseases, with their involvement substantially higher at later stages, especially Phase III.
Smaller biotech companies are participating in the development of 85 (42%) of the vaccines included in the analysis, and are generally focused on early stage development from discovery through Phase I – although, increasingly, those companies are actively engaged through Phase II research.
Pharmaceutical R&D investment for neglected diseases reached USD 527.2 million in 2012, an annual increase of 3.7%.NTDs Ifpma.
Pharmaceutical industry is the 3rd largest funder of R&D for neglected diseases, after the public and philanthropic sectors. NTDs Ifpma.
1 BIO Ventures for Global Health. Developing new drugs & vaccines for neglected diseases of the poor. The Product Developer Landscape; March 2012
2 Vaccines in Development, PhRMA 2012 Report